Dr. Reddy’s is offering Reddy-Lenalidomide, a generic of Revlimid, in the Canadian market. Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada.
The product is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
“Our launch of Reddy-Lenalidomide represents our firm commitment to providing access to affordable medicines for Canada’s Multiple Myeloma and Myelodysplastic Syndrome patient population,” said Vinod Ramachandran, vice president and general manager, Dr. Reddy’s Labs Canada.
“Along with this important launch, we are pleased to introduce our Reddy2Assist Platform, which provides convenient one-stop access to assist prescribers and pharmacists with qualification requirements for patients, as well as patient onboarding and registration via web portal, telephone or fax.”
Reddy-Lenalidomide capsules are available in dosage strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg, all of which are sold in blister packs.